Avoiding the pitfalls: 5 lessons for cell therapy manufacturing success

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Avoiding the pitfalls: 5 lessons for cell therapy manufacturing success

As cell therapies move from development to commercialization, the path becomes increasingly complex. This webinar offers a practical, experience-driven guide to navigating five critical missteps cell therapy companies make during clinical development and the transition to commercial manufacturing. From selecting CDMOs without long-term alignment to underestimating logistical or regulatory challenges, our experts will share insights on how to avoid these pitfalls and achieve innovation readiness for your cell therapy manufacturing strategy, whether autologous or allogeneic.

Whether you’re preparing to enter the clinic, planning for biologics marketing authorization submission, scaling for launch, or reassessing your current manufacturing strategy, this webinar will offer practical takeaways to help you position your therapy for sustainable success. Technologies and processes for cell therapies, such as CAR-T and HSC-based therapies, will be discussed with a forward-looking perspective on infrastructure and innovation readiness.

Attend this webinar to:

• Learn about the importance of phase-appropriate cell therapy manufacturing strategies, including automation

• Differentiate between clinical-stage and commercial-stage manufacturing needs, and design late-stage operations with launch-readiness in mind

• Gain clarity on how to evaluate CDMO capabilities beyond surface-level metrics to de-risk your commercialization journey

Joseph Garrity

Executive Director, Portfolio Management at Lonza

Joe Garrity, Executive Director of Portfolio Management, is a key member of the leadership team within the Specialized Modalities Platform at Lonza. He plays a central role in driving the strategic development and expansion of the platform portfolio. Joe collaborates closely with teams across operations, development, and quality to optimize and align clinical and commercial manufacturing services offered by Lonza. He holds an academic background in biochemistry and brings over a decade of experience in the cell and gene therapy CDMO sector, having held leadership roles spanning development, operations, and business functions.

You have registered for this webinar